Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06NXG
|
|||
| Former ID |
DNCL001642
|
|||
| Drug Name |
PF-04236921
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [2] | ||
| Company |
Pfizer New York, NY
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01405196) Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus. U.S. National Institutes of Health. | |||
| REF 3 | US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.